- Home
- AYTU vs RDHL Comparison
AYTU vs RDHL Comparison
Compare AYTU & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- RDHL
- Stock Information
- Founded
- AYTU N/A
- RDHL 2009
- Country
- AYTU United States
- RDHL Israel
- Employees
- AYTU N/A
- RDHL N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- AYTU Health Care
- RDHL Health Care
- Exchange
- AYTU Nasdaq
- RDHL Nasdaq
- Market Cap
- AYTU 15.0M
- RDHL 13.1M
- IPO Year
- AYTU N/A
- RDHL N/A
- Fundamental
- Price
- AYTU $2.21
- RDHL $8.07
- Analyst Decision
- AYTU
- RDHL
- Analyst Count
- AYTU 0
- RDHL 0
- Target Price
- AYTU N/A
- RDHL N/A
- AVG Volume (30 Days)
- AYTU 30.7K
- RDHL 26.7K
- Earning Date
- AYTU 11-12-2024
- RDHL 10-15-2024
- Dividend Yield
- AYTU N/A
- RDHL N/A
- EPS Growth
- AYTU N/A
- RDHL N/A
- EPS
- AYTU N/A
- RDHL N/A
- Revenue
- AYTU $81,002,000.00
- RDHL $3,707,000.00
- Revenue This Year
- AYTU N/A
- RDHL $224.90
- Revenue Next Year
- AYTU N/A
- RDHL $82.69
- P/E Ratio
- AYTU N/A
- RDHL N/A
- Revenue Growth
- AYTU N/A
- RDHL N/A
- 52 Week Low
- AYTU $2.20
- RDHL $6.43
- 52 Week High
- AYTU $3.50
- RDHL $82.00
- Technical
- Relative Strength Index (RSI)
- AYTU 39.00
- RDHL 40.51
- Support Level
- AYTU $2.26
- RDHL $7.95
- Resistance Level
- AYTU $2.44
- RDHL $8.50
- Average True Range (ATR)
- AYTU 0.14
- RDHL 0.59
- MACD
- AYTU -0.02
- RDHL -0.13
- Stochastic Oscillator
- AYTU 2.03
- RDHL 3.85
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.